Jefferies Starts BridgeBio Pharma (BBIO) at Buy

Jefferies analyst Andrew Tsai initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Buy rating and a price target of $70.00.

The analyst comments: "We believe Attruby (oral TTR stabilizer) could become a $4B+ blockbuster pill in ATTR-CM heart disorder (a pot'l $20B TAM). We like the risk/reward at $8.8B cap, since $4B sales x 3x multiple = $12B valuation already, with our doc checks suggesting add'l upside if Attruby's real-world efficacy proves differentiated over PFE's tafamidis. Behind Attruby includes three pot'l regulatory filings in 2026 for various rare diseases, providing the next leg of growth."

For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.

Shares of BridgeBio Pharma closed at $46.47 yesterday.

You May Also Be Interested In